The U.S. Food and Drug Administration (FDA) has approved Triumeq, ViiV Healthcare's single-tablet, triple-combination antiretroviral (ARV) regimen, as a first-line therapy to treat HIV. The tablet is comprised of the integrase inhibitor dolutegravir (Tivicay) plus abacavir and lamivudine (Kivexa/Epzicom) and is the first single-tablet regimen to receive approval that does not contain tenofovir.
26 August 2014 | Aidsmeds.com
A family of proteins that helps viruses, such as HIV and Ebola, enter a cell also can block the release of those viruses. When HIV-1 or any virus infects a cell, it replicates and spreads to other cells. One type of cellular protein—T cell immunoglobulin and mucin domain, or TIM-1—has previously been shown to promote entry of some highly pathogenic viruses into host cells. Researchers have now discovered that the same protein possesses a unique ability to block the release of such viruses. The findings are published in the Proceedings of the National Academy of Sciences.
“This is a surprising finding that provides new insights into our understanding of not only HIV infection, but also that of Ebola and other viruses,” says Shan-Lu Liu, associate professor of molecular microbiology and immunology at University of Missouri.
26 August 2014 | Futurity
Theraclone Sciences Inc. of Seattle said it's made a deal with Gilead Sciences Inc. that will allow the Foster City-based biotech giant to develop and commercialize Theraclone's neutralizing HIV-antibodies for therapeutic applications in HIV.
31 July 2014 | San Francisco Business Times (blog)
The licence will allow manufacturers in India and China to develop generic versions of TAF for 112 countries that are home to more than 92% of people living with HIV in the developing world.
25 July 2014 | Medicines Patent Pool
Drugs, diagnostics, vaccines, preventive technologies, research towards a cure, and immune-based and gene therapies in development.
21 July 2014 | Treatment Action Group & i-Base
ViiV Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for Triumeq® (dolutegravir/abacavir/lamivudine) for the treatment of HIV infection in adults and adolescents aged 12 years and older and weighing at least 40kg.
30 June 2014 | Viiv Healthcare press release
The German Institute for Quality and Efficiency in Health Care (IQWiG) has determined that the new integrase inhibitor drug dolutegravir (Tivicay ®) is of considerable added benefit to treatment-naive patients in comparison with current first-line therapies, and some added benefit to patients who already need to take an integrase inhibitor.
19 June 2014 | Science Daily
Glaxo’s majority-owned ViiV Healthcare venture is collaborating with Johnson & Johnson’s Janssen unit to test a pill combining ViiV’s Tivicay with Janssen’s Edurant, ViiV said today in a statement. Trials are expected to begin next year, the Brentford, U.K.-based company said.
13 June 2014 | Bloomberg
"Popular" cells - could there really be such a thing? According to a new opinion paper published in PLoS Pathogens, the human body may contain cells that have more contact with other cells and could be "superspreaders" of the HIV virus.
11 June 2014 | HIV / AIDS News From Medical News Today
Merck (MSD) today announced that the first patient has been enrolled in the company’s global Phase 3 clinical trial, ONCEMRK. ONCEMRK is assessing a once-daily investigational formulation of ISENTRESS® (raltegravir), known as reformulated raltegravir, as part of combination HIV therapy for treatment-naïve HIV-1-infected adults. Raltegravir combines high potency with low toxicity but its more widespread use has been held back by its needing to be taken twice a day.
06 June 2014 | Merck